Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Haferlach

Showing results (11-20 of 195) with videos related to

Pageof 20
Sort By:
Blood Cancer Journal|December 10, 2016
Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosisS Weber, T Haferlach, C Haferlach, et al.
Onkologie|August 1, 1986
[A comparison of staging classifications of plasmacytoma]H Löffler, W Gassmann, T Haferlach, et al.
The Clinical Investigator|October 1, 1993
Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapseT Haferlach, H Löffler, B Glass, et al.
Journal of the American Academy of Dermatology|January 1, 1996
Multiple myeloma first presenting as cutaneous plasmacytomaA Hauschild, T Haferlach, H Löffler, et al.
Annals of Hematology|November 15, 2003
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT)J Christodoulou, C Schoch, S Schnittger, et al.
Annals of Hematology|May 6, 2004
Modern diagnostics in chronic myeloproliferative diseases (CMPDs)T Haferlach, W Kern, S Schnittger, et al.
Deutsche Medizinische Wochenschrift (1946)|October 25, 2002
[Diagnostics and therapy of acute myeloid leukemia]W Kern, T Haferlach, C Schoch, et al.
Deutsche Medizinische Wochenschrift (1946)|October 25, 2002
[Diagnosis of leukemia using microarray technology]A Kohlmann, C Schoch, S Schnittger, et al.
Leukemia|November 11, 2006
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AMLS Schnittger, U Bacher, W Kern, et al.
Leukemia|October 31, 2003
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AMLC Schoch, W Kern, S Schnittger, et al.
Pageof 20

Showing results (11-20 of 195) with videos related to

Sort By:
Pageof 20
Blood Cancer Journal|December 10, 2016
Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosisS Weber, T Haferlach, C Haferlach, et al.
Onkologie|August 1, 1986
[A comparison of staging classifications of plasmacytoma]H Löffler, W Gassmann, T Haferlach, et al.
The Clinical Investigator|October 1, 1993
Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapseT Haferlach, H Löffler, B Glass, et al.
Journal of the American Academy of Dermatology|January 1, 1996
Multiple myeloma first presenting as cutaneous plasmacytomaA Hauschild, T Haferlach, H Löffler, et al.
Annals of Hematology|November 15, 2003
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT)J Christodoulou, C Schoch, S Schnittger, et al.
Annals of Hematology|May 6, 2004
Modern diagnostics in chronic myeloproliferative diseases (CMPDs)T Haferlach, W Kern, S Schnittger, et al.
Deutsche Medizinische Wochenschrift (1946)|October 25, 2002
[Diagnostics and therapy of acute myeloid leukemia]W Kern, T Haferlach, C Schoch, et al.
Deutsche Medizinische Wochenschrift (1946)|October 25, 2002
[Diagnosis of leukemia using microarray technology]A Kohlmann, C Schoch, S Schnittger, et al.
Leukemia|November 11, 2006
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AMLS Schnittger, U Bacher, W Kern, et al.
Leukemia|October 31, 2003
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AMLC Schoch, W Kern, S Schnittger, et al.
Pageof 20